H eart failure (HF) affects approximately 5 million Americans. 1 Whether the problem is chronic HF or acute management of patients with episodes of acute decompensated heart failure (ADHF), HF has proven to be a huge economic burden, with annual direct and indirect health care costs currently exceeding $34.4 billion. 1 Annual incidence rates are continuing to climb, with current statistics revealing 550,000 new cases every year, in addition to significant morbidity and mortality rates associated with multiple rehospitalization. 1 HF patients, even if stable and compliant with their current HF medication regimen, can quickly transition to an acute decompensated state at any time. Prevention of readmissions has become a national priority, and there is a growing fiscal incentive for health care institutions to develop strategies to smooth the transition from hospital to home and to provide more effective ambulatory HF treatment to keep patients out of the hospital. A multidisciplinary approach to management of this patient population has clearly provided an improvement in clinical outcomes. 2 Pharmacists are important members of this multidisciplinary team. This article reviews the current documented role of pharmacists in the care of HF patients and discusses the future evolution of pharmacists' role as the nation continues to develop innovative strategies in managing HF patients.
■■ Methods
Peer-reviewed intervention trials, descriptive studies, and review articles were identified in MEDLINE and Current Contents Connect database, from 1966 to April 2013, using the search terms "pharmacists," "pharmaceutical care," "clinical pharmacy services," "heart failure," and "cardiomyopathy." Citations from available articles were also reviewed for additional references. Table 1 summarizes pertinent studies described below.
■■ Evidence Documenting the Role of Pharmacists in HF Care
The role of pharmacists in the care of HF is diverse and well described in the literature. Pharmacists generally provided care either as a sole practitioner or, more commonly, as part of a multidisciplinary team. The specific responsibility described varied and likely depended on the specific patient population, setting, and role of other health care team members. The sections that follow describe the documented roles and responsibilities of pharmacists in the care of HF patients.
C O M M E N TA R Y

Medication Reconciliation and Education
Medication reconciliation and patient education are 2 major areas and responsibilities of pharmacists that are now established to positively impact clinical outcomes of patients with different disease states. 3, 4 The effect of a clinical pharmacist on reconciliation of discharge medication of a HF patient population was evaluated in a study by Eggink et al. (2010) . 5 The aim of this study was to evaluate the effect of a clinical pharmacist discharge service on medication discrepancies and prescription errors. This open-label, randomized intervention study compared an intervention group with a control group receiving regular care by doctors and nurses. The role of the clinical pharmacist discharge service included review of medications at discharge, communicating prescribing errors with the cardiologists, preparing written overviews of the discharge medications, and communication with community pharmacists and patients' primary care physicians about their medications, in order to establish a continuum of care. All patients were scheduled to return for a clinic visit with the discharge clinicians, and at that time, medication discrepancies were measured. The primary study endpoint was the frequency of prescription errors in discharge medications and medication after discharge combined. The control group included 44 patients, with 41 in the intervention group. In the control group, 68% of patients had at least 1 discrepancy versus 39% in the intervention group (relative risk [RR] = 0.57; 95% confidence interval [CI] = 0.37-0.88). This study validates the significant value of a clinical pharmacist discharge service in patients with HF.
In the Pharmacist Intervention for Low Literacy in Cardiovascular Disease (PILL-CVD) study, the effects of pharmacist-based medication reconciliation for patients with acute coronary syndrome or ADHF were evaluated. 6 In this randomized controlled trial, 2 academic health care centers enrolled eligible patients and randomized them to usual care or usual care plus pharmacist intervention. Pharmacist interventions included obtaining in-depth medication history on admission, performing detailed medication reconciliation on admission and discharge, and offering patient medication education on discharge. Various methods were used to assist in the process of medication reconciliation, including pillboxes, verbal and written instruction, and telephone follow-up. The primary outcome was the number of clinically important medication errors per patient during the first 30 days after hospital discharge. Among 851 participants, 432 (50.8%) had 1 or more clinically Outpatient clinic service Before and after intervention comparison
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• Improvement in symptoms Stewart et al. 13, 14 Intervention prior to discharge with follow-up This study revealed greater benefit from medication reconciliation in low-literacy patients, with nonsignificant benefit attained in high-literacy patients. In a follow-up substudy evaluating perspectivces of 11 pharmacists (from the PILL-CVD study) on the value of the intervention, 7 the pharmacists viewed medication reconciliation as the greatest and most important portion of the intervention in improving patient care transitions. The pharmacists also identified groups of patients who may be in greater need of medication reconciliation, particularly patients on multiple medications. Adherence aids such as pillboxes were more effective for patients with low health literacy as opposed to patients with adequate health literacy. Pharmacists' recommendations acknowledged a need for clear communications among team members, protected time for discharge counseling, and provision of tailored patient counseling for improved transitions of patient care.
Medication Initiation, Dosage Titration, Adjustment, and Monitoring
Although clinical evidence and treatment guidelines clearly mandate the use of evidence-based therapies such as angiotensin converting enzyme inhibitors (ACEI) and beta blockers in HF patients, these therapies are well known to be suboptimal when prescribed in actual clinical settings. 8 The Acute Decompensated Heart Failure National Registry (ADHERE) collected HF case data from more than 275 hospitals in the United States and captured data on more than 40,000 patients hospitalized for HF. Data from the third quarter of 2004 revealed that clinicians had prescribed ACEI for 54% of patients at discharge, and use of ACEI or angiotensin receptor blocker (ARB) was approximately 68%. 9 In addition, clinicians prescribed beta blockers for 72% of discharged patients. 9 These data were encouraging compared with data previously reported and reflected better use of evidence-based therapies. Although prescribing does appear to be gradually improving, the use of ACEI and beta blockers for those at highest risk was still less than optimal. From the Enhanced Feedback for Effective Cardiac Treatment trial, a population-based cohort of patients with HF who were hospitalized in Ontario, Canada, from 1999 through 2001 (9,942 patients), patients with left ventricular ejection fraction of less than 40% and those younger than 79 years (1,418 patients) were assessed. 10 HF drug use at time of discharge and 90 days after discharge was determined, and patients were categorized as being at low, average, or high risk for death. In these 3 risk groups, ACEI prescribing was 81%, 73%, and 60% at discharge and 83%, 76%, and 61% within 90 days after discharge, respectively. For ACEIs or angiotensin II receptor blockers (ARB), prescribing was 86%, 80%, and 65% at discharge and 89%, 83%, and 67% within 90 days after discharge, respectively. In addition, prescribing rate was 40%, 33%, and 24% at discharge for beta blockers and 43%, 36%, and 28% within 90 days after discharge, respectively. Compared with high-risk patients, low-risk patients were more likely to receive drug therapy with ACEI or ARB (adjusted hazard ratio [HR] = 1.61; 95% CI = 1.49-1.74) and beta blockers (adjusted HR = 1.80; 95% CI = 1.60-2.01).
Jain et al. (2005) evaluated the effectiveness of a protocoldriven HF clinic staffed by nurses and pharmacists for improving symptoms and optimizing treatment with therapeutic agents that have been demonstrated to improve mortality, without adversely affecting renal function. 11 Of the 234 patients with at least 1 follow-up visit, 127 (57%) were receiving none or only 1 key therapeutic agent when first seen, a number that was reduced to 25 patients (11%) at most recent follow-up. The improvement in prescription rates was accompanied by significant uptitration of dose, with the proportion of patients on "medium" or "high" doses rising from 43 (18%) to 134 (57%) for beta blockers and from 129 (55%) to 201 (86%) for ACEI/ ARB. Clinical improvement was reflected in reductions in patients with New York Heart Association (NYHA) functional classes III and IV (93 [40%] to 53 [23%]) and in patients with moderate or severe symptoms. Uptitration of treatment was associated with reductions in heart rate and systolic blood pressure. Incidence of hyperkalemia and worsening of renal function was low. This study, however, did not differentiate the specific impact made by a nurse versus a pharmacist.
Other studies have also examined having a pharmacist on a multidisciplinary team to provide medication dosing recommendations (although not specifically targeted on just dose titration), which also improved patient outcome. Those studies are described in more detail in the next 2 sections.
Development of Disease Management Pathway
Disease management pathways have been demonstrated to efficiently improve care, especially in high-cost, high-volume, and high-risk diagnoses. 12 HF is considered a high-cost, highvolume, high-risk diagnosis. Therefore, although there are no specific clinical studies of pharmacists developing and using disease management pathways to improve HF patient care, we anticipate that these pathways will improve the efficiency of care of such patients. Pharmacists play an important role on a team evaluating the pathway that requires appropriate drug use. Selection of a standard set of drugs to be used in the pathway should be based on the health system's formulary, with a process in which new information on disease management, including available drug therapies, can be incorporated. By incorporating evidence-based, rational, cost-effective therapy into critical pathways, pharmacists can ensure that interventions are consistent with local pharmacy department policies and procedures and with other hospital committee policies. Pharmacists can also prospectively design drug use evaluation in such a way that areas of the critical pathway involving safety, adherence, variation, and efficacy, including specifically designated outcomes, can be assessed.
Posthospital Discharge Follow-Up, Clinic, and Home Visit Perhaps the pharmacist role most extensively researched and documented in HF patient management is the evaluation of such service in an "outpatient" or "postdischarge" setting, such as in clinics or in the community. Stewart et al. (1998) evaluated the impact of a home-based intervention among 97 patients with HF, who were discharged from an acute care hospital. 13 The intervention was delivered by a nurse and a pharmacist and involved a single home visit within 1 week postdischarge to optimize medication management, identify early clinical deterioration, and identify whether medical follow-up was necessary. The effects of these home-based interventions were compared with standard postdischarge care. The predischarge counseling was done by the nurse, whereas the home visit involved both a nurse and a pharmacist. The pharmacist's role during the home visit included performing an assessment of the patient's knowledge of prescribed medications and compliance. Patients who had poor medication knowledge and/or demonstrated nonadherence to a medication regimen received the following supports: verbal medication counseling, daily reminder to take medications, a dosage administration aid (such as a pillbox) to enable predistribution of medications, provision of a medication information and reminder card, increased monitoring by caregivers, and referral to a community pharmacist for regular medication review. The main outcome measures were the frequency of unplanned readmissions and out-of-hospital deaths in 6 months. Patients in the intervention group had fewer unplanned readmissions (36 vs. 63, P = 0.03) and fewer out-ofhospital deaths (1 vs. 5, P = 0.11). Patients in the control group who received usual care had more days of hospitalization (261 vs. 452; P = 0.05). This study, however, did not specifically measure the impact on patient outcome made by the pharmacist.
In 1999, the same group of investigators carried out an extended 12-month follow-up study of all surviving patients from the previous 1998 study. 14 This follow-up demonstrated fewer unplanned readmissions, out-of-hospital deaths, and days of hospitalization for the home-based intervention patients. There was also a significant lowering in hospitalbased costs. Goodyer et al. (1995) conducted a study to determine whether pharmacists providing intensive counseling to elderly patients with chronic HF can influence subjective and objective measures of HF. 15 The randomized patients received either a 3-month counseling program or no counseling at all. Patients in the intervention group were counseled on their medications using a "standard written protocol," the details of which were not provided. Compliance was measured by a tablet count, whereas medication knowledge was assessed using a questionnaire. Mean compliance scores by tablet count were calculated, the mean indicating the percentage of the maximum number of tablets that should have been consumed. At the beginning of the study, mean compliance was 49% in the control group as compared with 61% for the intervention group, which was not statistically significant (P = 0.98). After the counseling program, compliance was significantly higher in the intervention group (93% vs. 51%, P < 0.001). Medication knowledge also improved significantly (P < 0.001). However, precise details of this improvement were not provided. A 6-minute exercise test that was carried out at the beginning and end of the study demonstrated worse results for the control group at the end of the study period. In the intervention group, these test results improved, suggesting that counseling improved the patient's medication compliance, which in turn led to improved exercise capacity. Patients who received medication counseling also demonstrated improved signs of edema, which was attributed to improved medication compliance.
Varma et al. (1999) 16 evaluated a structured pharmaceutical care program for patients with HF aged more than 65 years. The intervention group of patients (group A) received education from a pharmacist on the disease state and on the medications and management of HF symptoms, as well as an information booklet containing the discussed information. Patients were also encouraged to monitor their symptoms and comply with their medications. Patients were asked to self-monitor using diary cards to be shown to their physicians and community pharmacists and later mailed to the researchers. Group A also recorded their weight on a daily basis and adjusted their diuretic doses accordingly, based on a specific increase in weight or on a worsening of symptoms, such as increased shortness of breath or ankle swelling. The pharmacist-researcher contacted the community pharmacists and physicians via telephone to discuss the project and the self-monitoring program. Patients in the control group (group B) received standard management. All patients were assessed at baseline and at 3, 6, 9, and 12 months for the following: 2-minute walk test, blood pressure, body weight, pulse, quality of life, knowledge of symptoms and drugs, compliance with therapy, and use of health care facilities. From these assessments, patients in group A demonstrated better compliance with drug therapy, which led to improved exercise capacity compared with patients in group B. Over the 12 months of this study, group A patients also exhibited considerable enhanced knowledge of their drug therapy and had fewer hospital admissions compared with group B patients. Quality of life, as an outcome, was not shown to have statistically significant changes following pharmacy interventions when compared with usual care.
Gattis et al. (1999) 17 conducted the Pharmacist in Heart Failure Assessment Recommendation and Monitoring Study, to examine the benefits of the addition of a clinical pharmacist to the HF management team on outcomes in outpatients with HF. In the intervention group, patients attended an outpatient clinic and received extensive medication education and counseling provided by a clinical pharmacist. The pharmacist discussed and optimized the patient's drug regimen by collaborating with the patient's physician, implemented changes to the patient's HF drug therapy, and then discussed the changes with the patient. Follow-up was conducted via telephone at 2, 12, and 24 weeks after the initial clinic visit to identify any issues with drug therapy. The control group patients received usual care. Primary endpoint was the combination of all-cause mortality and nonfatal HF events (i.e., emergency department visits or hospitalizations for HF). There were 4 events in the intervention group as compared with 16 in the control group. The effect on all-cause mortality was not found to be statistically significant, but the effect on nonfatal HF events was significant. This difference may be because of the closer follow-up by the clinical pharmacist of the patients in the intervention group. This close follow-up may have led to the early recognition of signs and symptoms of fluid overload, which in turn allowed quicker reviews by the physician and dose adjustments of diuretics, preventing the deterioration of HF. In addition, patients in the intervention group were more likely to receive target ACE inhibitor doses. The follow-up by the pharmacist also allowed the re-evaluation of the patient's medication regimen, recognition of potential drug interactions, the significance of medication compliance, and the reinforcement of dietary sodium intake. 17 In a study based in an acute care facility in the United States, Rainville (1999) 18 evaluated the impact of pharmacist interventions on the functional health status of HF patients and their rate of readmissions. The patients, nurses, and physicians were blinded to the allocation to minimize the potential for bias. Control group patients received routine care, which involved written prescriptions, physician-discharged instructions, a nurse review of diet, treatment plan, medication, and drug information sheets. The intervention group received routine care plus education from a pharmacist and nurse specialist, and patient issues that could contribute to readmission were also identified and corrected if necessary. The pharmacist also reviewed the pharmacotherapy and pathology of HF with the patient or their caregiver, monitored the patient's weight, and reviewed risk modifications. In addition, the pharmacist provided a patient information brochure, medication organizer, weight log booklet, and video tape, and the pharmacist recommended medication changes to the physician when necessary.
Both patient groups received a follow-up telephone call after 30 days, 90 days, and 12 months of postdischarge. Patients in the intervention group also received a telephone follow-up 3 and 7 days postdischarge. There was a significant improvement in hospital readmissions for HF in the intervention group as compared with the control group (24% vs. 59%) over the 12-month period. In addition, there was a significantly longer time to readmission for the patients in the intervention group. The author concluded that the pharmacist intervention in this study "led to significantly fewer readmissions for HF," noting that the validity of this study would need to be evaluated in a larger study. 18 Whellan et al. (2001) 19 undertook a study to evaluate the potential benefit of implementing an HF disease management program, the Duke Heart Failure Program (DHFP). This study assessed the benefits of beta blocker use and the cost to the health care system. The outcomes were assessed based on the rates of pre-enrollment versus postenrollment into the program. Although this study involved a myriad of health professionals, the role of the pharmacist was clearly stated as reviewing medications with the patient and providing a medication appraisal for the physician. The pharmacist, with the help of the nurse, emphasized weight monitoring and when to contact a DHFP nurse in the event of experiencing worsening symptoms. The results showed that both beta blocker usage and doses increased significantly during the study, whereas hospitalization rates significantly decreased, and the number of clinic visits significantly increased. The doses of ACEIs used increased, although not significantly. This increase could reflect the increased prescribing rates of ACEIs and beta blockers that occurred over the course of the study. 19 The role of pharmacists as part of a pilot HF program to help prevent exacerbations and hospitalizations among HF patients was evaluated in a 2003 study by Patel et al. 20 The intervention group received pharmacist interventions such as drug therapy evaluation, telephone counseling, and recommended drug therapy changes sent to the physician by telephone or fax. Patients received pharmacist interventions every 4 to 6 weeks for 6 months, and outcomes were evaluated after 3 and 6 months. There was no difference in the number of hospitalizations between the intervention and control groups. This study, however, was limited by a very small sample size (n = 18). 20 Lowrie et al. (2012) 21 performed a randomized controlled study, where 1,090 HF patients from 87 primary care practices were randomized to pharmacist intervention or usual care. The intervention was delivered by nonspecialist pharmacists working with family doctors to optimize medical treatment. The primary outcome was a composite of death or hospital admission for worsening HF. The median follow-up was 4.7 years. At baseline, 86% of patients in both groups were treated with an ACEI or an ARB. In patients not receiving one or other of these medications, or receiving less than the admission (RR = 0.87; 95% CI = 0.79-0.95), although significant heterogeneity was found among studies (P = 0.002). All-cause mortality was also reduced (RR = 0.79; 95% CI = 0.69-0.92) as was HF admission (RR = 0.70; 95% CI = 0.61-0.81). These results varied little with sensitivity analyses.
Koshman et al. (2008) 25 also performed a systematic review to specifically characterize the role of pharmacists in the care of patients with heart failure. They identified 12 randomized controlled studies. The extent of involvement of the pharmacist varied among studies, and each study intervention was categorized as pharmacist-directed care or pharmacist-collaborative care. Pharmacist care was associated with significant reductions in the rate of all-cause hospitalizations (11 studies [ 
■■ Potential Future Roles for HF Pharmacists Management of Mechanical Circulatory Support
Advances in mechanical circulatory support, such as the use of ventricular assist devices (VADs), and total artificial heart systems have become a means for prolonging survival in end-stage HF. VADs decrease the symptoms of HF and improve quality of life. They unload the ventricle to provide improved cardiac output and end-organ perfusion, resulting in improvement in cardiorenal syndromes and NYHA functional class rating. VADs are currently used as a bridge to heart transplantation, a bridge to recovery of cardiac function, or as destination therapy. Total artificial heart systems are currently used as a bridge to heart transplantation. Complications of VAD and total artificial heart systems may include bleeding and thrombosis, infections, arrhythmias, multiple organ failure, right ventricular failure, and neurological dysfunction. Patients with VAD and an artificial heart have unique pharmacotherapeutic requirements in terms of anticoagulation, appropriate antibiotic selection, and continuation of HF medications. Because evidence available in managing this patient population is still sparse compared with other areas of HF management, pharmacist expertise in pharmacology and therapeutics can really contribute to both acute care and community settings in optimizing patients' medication care. Jennings et al. (2011) 26 described establishing a clinical pharmacy service for patients with left VAD (LVAD). During the data collection period, the clinical pharmacist documented 400 interventions made in patients with LVADs (262 interventions on the cardiothoracic surgery service, recommended dose, treatment was started, or the dose increased, in 33.1% of patients in the intervention group and in 18.5% of the usual care group (odds ratio [OR] = 2.26; 95% CI = 1.64-3.10; P < 0.001). At baseline, 62% of each group was treated with a beta blocker and the proportions starting or having an increase in the dose were 17.9% in the intervention group and 11.1% in the usual care group (OR = 1.76; 95% CI = 1.31-2.35; P < 0.001). The primary outcome occurred in 35.8% of patients in the intervention group and 35.4% in the usual care group (HR = 0.97; 95% CI = 0.83-1.14; P = 0.72). The investigators concluded that a low-intensity, pharmacist-led collaborative intervention in primary care resulted in modest improvements in prescribing disease-modifying medications but did not improve clinical outcomes in a population that was relatively well treated at baseline.
Gwadry-Sridhar et al. (2005) 22 performed a randomized controlled pilot study, in which 134 patients with left ventricular dysfunction were placed in the intervention group, where they received education on medication adherence, diet, and lifestyle modification provided by a pharmacist and nurse educator compared with standard of care. Although intervention did not improve mortality, hospital readmission, or emergency department visits, patients demonstrated significant improvement in quality of life measured by the Minnesota Living with Heart Failure Questionnaire. This study did not differentiate the specific impact on patient outcome between the pharmacists and the nurse educators.
Lopez-Cabezas et al. (2006) 23 performed a randomized controlled trial enrolling 134 patients hospitalized for HF. Patients were randomized to standard of care or interventions including education on disease, diet, and drug therapy from a pharmacist at discharge, with monthly follow-up phone calls for 6 months and every 2 months after. The intervention group demonstrated significant reduction in hospital readmission at 2 months, 6 months, and 12 months (P < 0.05 at both time points).
Impact on Patient Outcomes
As discussed above, numerous studies have described the role of pharmacists in the care of HF patients. These studies demonstrated service performed with varied scope, in different settings, and with various outcome measures. Because some of these studies are small, and intervention may not be evaluated in a randomized fashion, meta-analysis and systematic reviews may be able to help us better determine the impact of these services to patient outcomes. Holland et al. (2005) 24 performed a systematic review of 30 randomized controlled trials conducted in both hospital and community settings, evaluating the impact of multidisciplinary team interventions on HF patient outcomes in terms of all-cause hospital admission, mortality, and HF hospital admission. Multidisciplinary interventions reduced all-cause ■■ Discussion HF is a high prevalence medical condition. Many medical and therapeutic advances have been made with respect to HF and its management. Despite these advances, therapeutic challenges still exist. The pharmacist plays a pivotal role in the management of HF patients through medication reconciliation, patient education, and collaborative medication management efforts. A substantive body of data shows that pharmacists, when actively engaged in these efforts, may decrease length of stay and reduce the number of readmissions. Furthermore, patient wellness and overall perception of self may be improved through educational efforts and active involvement in selfmonitoring of the symptoms of HF. The pharmacist's involvement in medication reconciliation and concurrent therapeutic recommendations at time of prescribing also lead to fewer prescribing errors and greater awareness of patient-specific needs for dosage adjustments or other therapeutic interventions. The multidisciplinary team approach, with inclusion of a pharmacist, improves patient outcomes in a multitude of ways. The American College of Clinical Pharmacy and the Heart Failure Society of America have published an opinion paper recently in support of clinical pharmacists participating in HF patient care, describing the potential roles for clinical pharmacists in a multidisciplinary HF team, recommending minimum training for clinical pharmacists engaged in HF care, and suggesting financial strategies to support clinical pharmacy services within a multidisciplinary team. 28 As the health care system continues to develop innovative approaches of care to minimize the burden of this disease, pharmacists will have an expanded role in the care of HF patients.
■■ Conclusions
Pharmacists as active participants in the care of HF patients may effect significant positive change in the therapeutic outcomes, decrease hospitalizations and readmissions, and improve overall patient perception of self. Medication reconciliation, patient education, and collaborative medication management are 3 major areas best documented in the literature in which a pharmacist may positively impact patient outcomes. Novel pharmacist roles may include medication management of patients with mechanical circulatory support for end-stage HF; pharmacist-run intravenous diuretic outpatient clinics, combined with concomitant patient education sessions; and provision of comprehensive medication management in a patient-centered medical home. The role of the pharmacist as liaison between patients and other health care providers is essential for effective management of a patient's HF medication therapy. Pharmacists should also be encouraged to prospectively evaluate their role in the care of this patient population, document their interventions, record cost avoidance, and document the relation to patient outcomes. average 8.7 interventions per patient encounter; 138 interventions on the acute heart failure service, average 1.8 interventions per patient encounter). Overall, the most common type of pharmacist intervention was change in dose/route/frequency (33%), followed by initiating evidence-based HF therapy (31%), discontinuing therapy (18%), ordering a laboratory test (12%), and changing therapy (6%). The most common reasons for pharmacist intervention were treatment of a disease or condition that was not controlled on present therapy (36%), followed by dose correction (17%), improved monitoring of drug therapy (13%), and adverse drug reaction/drug-drug interaction (11%). Antimicrobial agents were the most frequent medication class involved in pharmacist intervention. The role of pharmacists in this area will continue to expand as the use of mechanical devices in end-stage heart failure patients continues to increase.
Outpatient HF Infusion Clinic
The rate of hospital readmissions for ADHF is a major benchmark statistic for third-party payers, including Medicare and private insurers. A small pilot study has demonstrated that planned intravenous diuretic therapy administered in an outpatient setting may reduce heart failure hospital admissions and 30-day readmissions. 27 Many institutions across the United States have an interest in developing these clinics. Such settings provide another opportunity for pharmacists to work with other health care professionals not only to develop infusion protocols but also to optimize other medication therapy. In addition, such clinics allow pharmacists to work with patients directly through medication reconciliation, teaching, and improving medication adherence.
Patient-Centered Medical Home
Patient-centered medical home is a model of care where patients have a direct relationship with a provider who coordinates a cooperative team of health care professionals, including pharmacists, whether the patient is being seen at the doctor's office, becomes hospitalized, or is recuperating at home, through ongoing preventive care. Comprehensive medication management is an important part of care provided by the patient-centered medical home. Comprehensive medication management includes an individualized care plan that achieves the intended goals of therapy with appropriate follow-up to determine actual patient outcomes. Chronic HF is a disease state that is well suited to a patient-centered medical home model of coordinated care. The role of pharmacists in comprehensive medication management will be pivotal in improving overall patient outcomes.
